Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response
Top Cited Papers
- 1 December 2000
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 356 (9248), 2144-2148
- https://doi.org/10.1016/s0140-6736(00)03496-6
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Comparison of incremental and bolus dose inhaled allergen challenge in asthmatic patientsClinical & Experimental Allergy, 2000
- The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lungClinical & Experimental Allergy, 1999
- The late asthmatic response is associated with baseline allergen‐specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin‐5Clinical & Experimental Allergy, 1999
- Human eosinophilsJournal of Allergy and Clinical Immunology, 1997
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.The Journal of Experimental Medicine, 1996
- Reproducibility of allergen-induced early and late asthmatic responsesJournal of Allergy and Clinical Immunology, 1995
- Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation.JCI Insight, 1995
- The relationship between inflammation and hyperreactivity of the airways in asthmaClinical & Experimental Allergy, 1993
- Tolerance to the Nonbronchodilator Effects of Inhaled β2-Agonists in AsthmaThe New England Journal of Medicine, 1992
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991